History
Vectura was formed in 1997 with venture finance backing. Its aim was to develop and commercialise opportunities based on the technologies that were emerging in the fast- growing drug delivery field. Today, Vectura is an established company that specialises in the development of inhaled pharmaceuticals with a broad pipeline and a range of proprietary pulmonary delivery technologies. Its evolution can be charted as follows:
1999:
Vectura acquired Co-ordinated Drug Development Limited, owned by a group of academic pharmaceutical scientists, and the Centre for Drug Formulation Studies, established at the University of Bath. These two acquisitions provided a broad base of formulation expertise focused primarily on drugs for inhalation, an extensive intellectual property estate including a number of novel delivery technologies, an established development services business, and a team of research scientists.
2000:
Vectura collaborated with Arakis Ltd (now part of Sosei Group Corporation) in the development of AD237 (later NVA237) for the treatment of COPD.
2002:
Vectura acquired the Aspirair® inhaler technology and the associated device engineering team from Cambridge Consultants Ltd. Later that year Vectura moved to purpose-built premises in Chippenham.
2004:
Vectura listed on the London Stock Exchange on AiM.
2005:
Vectura entered into its first global commercialisation and development agreement with Novartis for NVA237.
2006:
Vectura entered significant licence and product development agreements with Boehringer Ingelheim and other major international pharmaceutical company partners based on Vectura’s proprietary device technologies and formulation development expertise.
2007:
Vectura acquired Innovata plc, a UK listed company that was developing pulmonary products using specialised device and formulation technologies and with a portfolio of marketed, revenue-generating products. In July 2007 Vectura moved from AIM to the Official List on the London Stock Exchange.
